{"id":2954,"date":"2017-09-14T09:30:07","date_gmt":"2017-09-14T13:30:07","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=2954"},"modified":"2017-09-14T09:30:07","modified_gmt":"2017-09-14T13:30:07","slug":"celcuity-llc-ipo-preview","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/celcuity-llc-ipo-preview\/","title":{"rendered":"Celcuity LLC IPO Preview"},"content":{"rendered":"

\"CelcuityLLClogo\"<\/a><\/p>\n

Company: Celcuity LLC<\/strong>
\nSymbol: CELC
\nDescription: They are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies.
\nShares: 2 million
\nRange: $8.00-$10.00
\nTrade Date: 9\/20
\nUnderwriter(s): Craig Hallum Capital Group<\/p>\n

Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Investor Access<\/strong>: This deal can be accessed via\u00a0Craig Hallum or by indicating through selling group, Motif. Click below to indicate with Motif.<\/p>\n

\"CelcuityMotif\"<\/a><\/p>\n

Business<\/strong>:\u00a0Their\u00a0proprietary CELx diagnostic platform is the only commercially ready technology they are aware of that uses a patient\u2019s living tumor cells to identify the specific abnormal cellular process driving a patient\u2019s cancer and the targeted therapy that best treats it. We believe our CELx platform provides two important improvements over traditional molecular diagnostics:<\/p>\n

    \n
  1. First, molecular diagnostics can only provide a snapshot of the genetic mutations present in a patient\u2019s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival. Cancer can develop when certain cell signaling activity becomes abnormal. Since genetic mutations are often only weakly correlated to the cell signaling activity driving a patient\u2019s cancer, a molecular diagnostic is prone to providing an incomplete diagnosis. CELx tests overcome this limitation by measuring real-time cell signaling activity in a patient\u2019s living tumor cells. When a CELx test detects abnormal signaling activity, a more accurate diagnosis of the patient\u2019s cancer driver is obtained.<\/li>\n
  2. Second, molecular diagnostics can only estimate the probability of a patient\u2019s potential drug response based on a statistical analysis of the drug\u2019s clinical trial results. Instead of this indirect estimate of drug response, CELx tests directly measure the effectiveness of a targeted therapy in a patient\u2019s living tumor cells. This enables physicians to confirm that the therapeutic matching the patient\u2019s cancer driver is functional in the patient\u2019s tumor cells before prescribing it, which significantly increases the likelihood of a positive clinical outcome.<\/li>\n<\/ol>\n

    OBJECTIVE RESPONSE RATES<\/strong><\/p>\n

    The table below provides objective response rates for representative targeted therapies that rely on a CDx to select eligible patients, as well as an example of the objective response rate for a targeted therapy that does not use a CDx to select eligible patients. The objective response rates listed below were obtained from the clinical trial data included with each of the targeted therapies respective FDA labels.<\/p>\n

    \"Screen<\/a><\/p>\n

    Competition and Sector Performance: Healthcare IPOs 2017<\/strong><\/p>\n